PhaseBio Pharmaceuticals, Inc. (PHAS)
EBITDA Growth
126.26%
TTM · Period ending:
PHAS EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported126.26%period ending
Latest reported126.26%period ending
PHAS TTM EBITDA YoY % (-140.97% → 126.26%)
Year-over-year change
High-resolution chart · PNG
PHAS ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| 126.2557% | |
| 116.4336% | |
| 101.7209% | |
| -46.6442% | |
| -67.1716% | |
| -139.3318% | |
| -154.2622% | |
| -145.1596% | |
| -132.0712% | |
| -90.2517% | |
| -91.7394% | |
| -91.8702% | |
| -140.9673% |